Type 2 diabetes mellitus (T2DM) is the most widespread form of diabetes, characterized by
chronic hyperglycaemia, insulin resistance, and inefficient insulin secretion and action …

Diabetes mellitus is a multifactorial disease, classically influenced by genetic determinants
of individual susceptibility and by environmental accelerating factors, such as lifestyle. It is …

Although patients with type 2 diabetes (T2D) are at significant risk for well‐recognized
diabetic complications, including macrovascular disease, retinopathy, nephropathy, and …

Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2
diabetes mellitus. Because many women with polycystic ovary syndrome (PCOS) are insulin …

There is growing evidence that the higher fracture rate observed in patients with type 2
diabetes mellitus (T2DM) is associated with normal, or even increased, areal bone mineral …

Patients with type 2 diabetes mellitus (T2DM) have an increased risk of fragility fractures
despite increased body weight and normal or higher bone mineral density. The mechanisms …

Anti‐diabetic drug metformin has been shown to enhance osteoblasts differentiation and
inhibit osteoclast differentiation in vitro and prevent bone loss in ovariectomized (OVX) rats …

Diabetes mellitus is associated with bone loss. Patients with type 2 diabetes are frequently
treated with oral antidiabetic drugs such as sulfonylureas, biguanides, and …

The prevalence of diabetes mellitus especially type 2 diabetes mellitus is increasing all over
the world. In addition to cardiomyopathy and nephropathy, diabetics are at higher risk of …

Background Metformin (MET) is widely used as a first-line hypoglycemic agent for the
treatment of type 2 diabetes mellitus (T2DM) and was also confirmed to have a therapeutic …